Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorapaxar in Japanese Subjects With Acute Coronary Syndrome
NCT00684203Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vorapaxar in acute coronary syndrome (ACS) (5 arms), sponsored by Merck & Co. Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) Who Underwent Percutaneous Coronary Interventions (PCI). Started Dec 2006; status: completed.
02
Drugs
vorapaxar
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00684203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684203.